|
gptkbp:instanceOf
|
gptkb:drug
synthetic progestogen
|
|
gptkbp:ATCCode
|
G03AC03
|
|
gptkbp:bioavailability
|
almost 100% (oral)
|
|
gptkbp:CASNumber
|
797-63-7
|
|
gptkbp:chemicalClass
|
19-nortestosterone derivative
|
|
gptkbp:contraindication
|
gptkb:cancer
known or suspected pregnancy
active liver disease
unexplained vaginal bleeding
|
|
gptkbp:discoveredBy
|
gptkb:Schering_AG
|
|
gptkbp:eliminationHalfLife
|
20–24 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C21H28O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
levonorgestrel
|
|
gptkbp:introducedIn
|
1960
|
|
gptkbp:isomerOf
|
gptkb:norgestrel
|
|
gptkbp:IUPACName
|
(17α)-17-hydroxy-13-ethyl-17-methylandrost-4-en-3-one
|
|
gptkbp:KEGGID
|
D00278
|
|
gptkbp:legalStatus
|
OTC (over-the-counter) in many countries
|
|
gptkbp:marketedAs
|
gptkb:Norplant
gptkb:Mirena
gptkb:Plan_B
|
|
gptkbp:mechanismOfAction
|
inhibits ovulation
alters endometrial lining
thickens cervical mucus
|
|
gptkbp:meltingPoint
|
232–239 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
312.45 g/mol
|
|
gptkbp:pregnancyCategory
|
Category D (Australia)
Category X (US)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1391
13109
12570
DB00367
|
|
gptkbp:routeOfAdministration
|
oral
intrauterine
subdermal implant
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
irregular menstrual bleeding
|
|
gptkbp:synonym
|
gptkb:(-)-norgestrel
gptkb:d-norgestrel
|
|
gptkbp:UNII
|
8N4SMC1RWB
|
|
gptkbp:usedFor
|
oral contraceptive
treatment of heavy menstrual bleeding
treatment of endometriosis
hormonal contraception
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Plan_B
|
|
gptkbp:bfsLayer
|
5
|